This week in therapeutics




Licensing status

Publication and contact information



MHC class I polypeptide-related sequence B (MICB); killer cell lectin-like receptor subfamily K member 1 (KLRK1; CD314; NKG2D)

Mouse studies suggest reducing circulating MICB levels could help treat cancer. In a mouse model of prostate cancer, expression of soluble human MICB, which is a ligand for the NK cell-activating receptor NKG2D, decreased peripheral NK cell levels and increased tumor growth and metastases compared with no MICB expression. In the model, a neutralizing antibody against MICB increased NK cell levels compared with an IgG control. Next steps include developing a humanized antibody targeting soluble MICB.

SciBX 6(40); doi:10.1038/scibx.2013.1123
Published online Oct. 17, 2013

Three patent applications filed; two available for licensing

Liu, G. et al. J. Clin. Invest.; published online Sept. 9, 2013;
Contact: Jennifer D. Wu, University of Washington, Seattle, Wash.